SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, and global healthcare leader Sanofi are strengthening their partnership to jointly target the preventive medicine market in Korea and abroad.

SK bioscience是一家全球创新疫苗和生物技术公司，致力于从预防到治疗促进人类健康，全球医疗保健领导者赛诺菲正在加强合作伙伴关系，共同瞄准韩国和国外的预防医学市场。

On January 23, SK bioscience announced that it had signed a co-promotion and distribution agreement with Sanofi Korea (hereafter referred to as Sanofi) for the respiratory syncytial virus (RSV) preventive antibody injection Beyfortus® and the hepatitis A vaccine Avaxim®. The contract period runs until the end of next year and may be extended upon mutual agreement.

。合同期限至明年年底，经双方同意可延长。

This agreement expands upon the distribution deal signed last year for five pediatric vaccines, including DTaP combination vaccines..

该协议扩大了去年签署的五种儿科疫苗的分销协议，包括DTaP联合疫苗。。

Approved in April last year in Korea, Beyfortus® is expected to bring significant changes to the RSV preventive medicine market by allowing all infants, not just high-risk groups, to receive protection during their first RSV infection season. RSV is one of the most common viral causes of respiratory infections, such as pneumonia and bronchiolitis, in infants.

Beyfortus®于去年4月在韩国获得批准，预计将通过允许所有婴儿（而不仅仅是高危人群）在第一个RSV感染季节接受保护，为RSV预防药物市场带来重大变化。RSV是婴儿呼吸道感染（如肺炎和毛细支气管炎）最常见的病毒原因之一。

It is also a leading cause of hospitalizations among infants. Approximately 90% of infants worldwide are infected with RSV before the age of two, and early infections are associated with longer recovery times and higher risks of asthma, emphasizing the importance of prevention and early treatment..

它也是婴儿住院的主要原因。全世界大约90%的婴儿在两岁之前感染了RSV，早期感染与更长的恢复时间和更高的哮喘风险有关，强调了预防和早期治疗的重要性。。

Beyfortus® is the only RSV preventive medicine available for all infants during their first RSV season. It offers a single-dose regimen with a minimum five-month protection period, covering the entire season. In 2023, it achieved €547 million (approximately KRW 821 billion) in global sales.

Beyfortus®是第一个RSV季节所有婴儿唯一可用的RSV预防药物。它提供单剂量方案，保护期至少为五个月，覆盖整个季节。2023年，其全球销售额达到5.47亿欧元（约8210亿韩元）。

Avaxim®, a hepatitis A vaccine manufactured in accordance with WHO recommendations, is widely used worldwide due to its high safety and efficacy. It has demonstrated excellent effectiveness in preventing hepatitis A.

Avaxim®是一种根据世卫组织建议生产的甲型肝炎疫苗，由于其高安全性和有效性而在世界范围内广泛使用。它在预防甲型肝炎方面表现出极好的效果。

Earlier in March last year, SK bioscience and Sanofi signed a distribution agreement for pediatric DTaP combination vaccines (Tetraxim®, Pentaxim®, and Hexaxim™), the adolescent and adult Tdap combination vaccine Adacel Prefilled Syringe®, and the meningococcal vaccine Menactra®. Notably, the six-in-one combination vaccine Hexaxim™ was officially included in the National Immunization Program (NIP) this year, further expanding its market presence.

去年3月初，SK bioscience和赛诺菲签署了儿科DTaP联合疫苗（Tetraxim®、Pentaxim®和Hexaxim™）、青少年和成人Tdap联合疫苗Adacel预充注射器®和脑膜炎球菌疫苗Menactra®的分销协议。值得注意的是，六合一组合疫苗Hexaxim™今年正式纳入国家免疫计划（NIP），进一步扩大了其市场占有率。

Hexaxim™ provides comprehensive protection against six infectious diseases (diphtheria, tetanus, pertussis, hepatitis B, polio, and invasive diseases caused by Haemophilus influenzae type b) and is the global market leader, holding a 67% share in the six-in-one combination vaccine category.With this expanded agreement, SK bioscience aims to solidify its position as a leading vaccine provider in the Korean market while strengthening its partnership with Sanofi.

Hexaxim™可全面预防六种传染病（白喉、破伤风、百日咳、乙型肝炎、脊髓灰质炎和B型流感嗜血杆菌引起的侵袭性疾病），是全球市场领导者，在六合一组合疫苗类别中占67%的份额。通过这项扩大的协议，SK bioscience旨在巩固其在韩国市场的领先疫苗供应商地位，同时加强与赛诺菲的合作关系。

Leveraging the R&D, production, and sales collaboration framework established with Sanofi, SK bioscience is also accelerating its entry into the global market. The two companies have been conducting Phase 3 clinical trials for a 21-valent pneumococcal conjugate vaccine since 2014. Additionally, at the end of last year, they signed a new agreement to jointly develop next-generation pneumococcal conjugate vaccines with broader protection for infants, children, and adults..

SK bioscience利用与赛诺菲建立的研发、生产和销售合作框架，也在加速进入全球市场。自2014年以来，两家公司一直在进行21价肺炎球菌结合疫苗的3期临床试验。此外，去年年底，他们签署了一项新协议，共同开发下一代肺炎球菌结合疫苗，为婴儿、儿童和成人提供更广泛的保护。。

Heekyung Park, Head of Vaccines at Sanofi Korea, stated, 'We are pleased to supply a variety of vaccines to the Korean market, including Beyfortus®, an RSV antibody injection for all infants under one year of age, through our strategic partnership with SK bioscience, a leading company in the Korean vaccine market.

赛诺菲（Sanofi Korea）疫苗主管朴喜庆（Heekyung Park）表示，“我们很高兴通过与韩国疫苗市场领先公司SK bioscience的战略合作关系，向韩国市场提供各种疫苗，包括Beyfortus®（一种针对所有一岁以下婴儿的RSV抗体注射液）。

Sanofi will continue its efforts to reduce the societal burden of infectious diseases and improve the preventive healthcare environment for infants and adults in Korea.'.

赛诺菲将继续努力减轻传染病的社会负担，改善韩国婴儿和成人的预防性医疗环境。”。

Jaeyong Ahn, CEO of SK bioscience,remarked, 'The co-promotion and distribution agreement for Sanofi products represents a significant step toward providing disease prevention benefits to both infants and adults, thereby enhancing public health. We will continue to collaborate with Sanofi, a global leader in the vaccine market, to jointly target both domestic and international markets.'.

SK bioscience首席执行官Jaeyong Ahn表示，“赛诺菲产品的共同推广和分销协议是朝着为婴儿和成人提供疾病预防益处，从而提高公共卫生水平迈出的重要一步。我们将继续与疫苗市场的全球领导者赛诺菲合作，共同瞄准国内和国际市场。”。

Source: skbioscience.com

来源：skbioscience.com